Back to results
US 11,141,352 B2Granted
Manufacture of peanut formulations for oral desensitization
AssigneeSociete des Produit Nestle S.A.
InventorsBryan Walser, Howard V. Raff
Life of this patent
Estimating the term…
Abstract
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.
Claims36
A method of making an allergenic powdered peanut flour formulation, comprising:
- (a) providing defatted peanut flour;
- (b) characterizing a concentration of each of Ara h1, Ara h2, and Ara h6 in the defatted peanut flour;
- and
- (c) mixing the defatted peanut flour with a lubricant, a glidant, or a diluent to form the allergenic powdered peanut flour formulation.
1 more element
A method of making an allergenic powdered peanut flour formulation, comprising:
- (a) mixing a defatted peanut flour with a lubricant, a glidant, or a diluent to form the allergenic powdered peanut flour formulation;
- and
- (b) characterizing a concentration of each of Ara h1, Ara h2, and Ara h6 in the allergenic powdered peanut flour formulation.
A method of making an allergenic peanut flour formulation, comprising:
- (a) providing defatted peanut flour;
- (b) characterizing a concentration of each of Ara h1, Ara h2, and Ara h6 in the defatted peanut flour by Reversed Phased-High Performance Liquid Chromatography (RP-HPLC);
- (c) mixing the defatted peanut flour with a lubricant, a glidant, or a diluent to form the allergenic peanut flour formulation;
- and
- (d) packaging the allergenic peanut flour formulation in a pharmaceutical dosage form.
2 more elements
A method of making an allergenic peanut flour formulation, comprising:
- (a) mixing a defatted peanut flour with a lubricant, a glidant, or a diluent to form the allergenic peanut flour formulation;
- (b) characterizing a concentration of each of Ara h1, Ara h2, and Ara h6 in the allergenic peanut flour formulation;
- (c) packaging the allergenic peanut flour formulation in a pharmaceutical dosage form.
Dependencies are inferred from the claim text.